Literature DB >> 24902904

RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis.

S Orozco1, N Yatim2, M R Werner3, H Tran3, S Y Gunja3, S W G Tait4, M L Albert2, D R Green5, A Oberst3.   

Abstract

Necroptosis is a form of programmed cell death that depends on the activation of receptor interacting protein kinase-1 (RIPK1) and RIPK3 by receptors such as tumor necrosis factor (TNF) receptor-1. Structural studies indicate that activation of RIPK3 by RIPK1 involves the formation of oligomers via interactions of the RIP homotypic interaction motif (RHIM) domains shared by both proteins; however, the molecular mechanisms by which this occurs are not fully understood. To gain insight into this process, we constructed versions of RIPK3 that could be induced to dimerize or oligomerize in response to a synthetic drug. Using this system, we find that although the formation of RIPK3 dimers is itself insufficient to trigger cell death, this dimerization seeds a RHIM-dependent complex, the propagation and stability of which is controlled by caspase-8 and RIPK1. Consistent with this idea, we find that chemically enforced oligomerization of RIPK3 is sufficient to induce necroptosis, independent of the presence of the RHIM domain, TNF stimulation or RIPK1 activity. Further, although RIPK1 contributes to TNF-mediated RIPK3 activation, we find that RIPK1 intrinsically suppresses spontaneous RIPK3 activation in the cytosol by controlling RIPK3 oligomerization. Cells lacking RIPK1 undergo increased spontaneous RIPK3-dependent death on accumulation of the RIPK3 protein, while cells containing a chemically inhibited or catalytically inactive form of RIPK1 are protected from this form of death. Together, these data indicate that RIPK1 can activate RIPK3 in response to receptor signaling, but also acts as a negative regulator of spontaneous RIPK3 activation in the cytosol.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24902904      PMCID: PMC4158689          DOI: 10.1038/cdd.2014.76

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  37 in total

1.  Activation of procaspases by FK506 binding protein-mediated oligomerization.

Authors:  David W Chang; Xiaolu Yang
Journal:  Sci STKE       Date:  2003-01-28

2.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

Authors:  T Clackson; W Yang; L W Rozamus; M Hatada; J F Amara; C T Rollins; L F Stevenson; S R Magari; S A Wood; N L Courage; X Lu; F Cerasoli; M Gilman; D A Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

3.  A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules.

Authors:  Laura A Banaszynski; Ling-Chun Chen; Lystranne A Maynard-Smith; A G Lisa Ooi; Thomas J Wandless
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

4.  The death domain kinase RIP mediates the TNF-induced NF-kappaB signal.

Authors:  M A Kelliher; S Grimm; Y Ishida; F Kuo; B Z Stanger; P Leder
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

5.  Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD.

Authors:  Tom Vanden Berghe; Geert van Loo; Xavier Saelens; Maria Van Gurp; Greet Brouckaert; Michael Kalai; Wim Declercq; Peter Vandenabeele
Journal:  J Biol Chem       Date:  2003-12-10       Impact factor: 5.157

6.  Tumour necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells.

Authors:  D Vercammen; P Vandenabeele; R Beyaert; W Declercq; W Fiers
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

7.  Identification of RIP1 kinase as a specific cellular target of necrostatins.

Authors:  Alexei Degterev; Junichi Hitomi; Megan Germscheid; Irene L Ch'en; Olga Korkina; Xin Teng; Derek Abbott; Gregory D Cuny; Chengye Yuan; Gerhard Wagner; Stephen M Hedrick; Scott A Gerber; Alexey Lugovskoy; Junying Yuan
Journal:  Nat Chem Biol       Date:  2008-05       Impact factor: 15.040

8.  TNF-alpha induces two distinct caspase-8 activation pathways.

Authors:  Lai Wang; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

9.  Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation.

Authors:  Yong Lin; Swati Choksi; Han-Ming Shen; Qing-Feng Yang; Gang Min Hur; You Sun Kim; Jamie Hong Tran; Sergei A Nedospasov; Zheng-gang Liu
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

10.  Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha.

Authors:  Sudan He; Lai Wang; Lin Miao; Tao Wang; Fenghe Du; Liping Zhao; Xiaodong Wang
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

View more
  134 in total

1.  Induction and Detection of Necroptotic Cell Death in Mammalian Cell Culture.

Authors:  Mikhail Chesnokov; Imran Khan; Ilana Chefetz
Journal:  Methods Mol Biol       Date:  2021

2.  RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4.

Authors:  Malek Najjar; Danish Saleh; Matija Zelic; Shoko Nogusa; Saumil Shah; Albert Tai; Joshua N Finger; Apostolos Polykratis; Peter J Gough; John Bertin; Michael Whalen; Manolis Pasparakis; Siddharth Balachandran; Michelle Kelliher; Alexander Poltorak; Alexei Degterev
Journal:  Immunity       Date:  2016-07-05       Impact factor: 31.745

3.  Herpes simplex virus 1 ICP6 impedes TNF receptor 1-induced necrosome assembly during compartmentalization to detergent-resistant membrane vesicles.

Authors:  Mohammad Ali; Linda Roback; Edward S Mocarski
Journal:  J Biol Chem       Date:  2018-11-30       Impact factor: 5.157

4.  Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity.

Authors:  Annelise G Snyder; Nicholas W Hubbard; Michelle N Messmer; Sigal B Kofman; Cassidy E Hagan; Susana L Orozco; Kristy Chiang; Brian P Daniels; David Baker; Andrew Oberst
Journal:  Sci Immunol       Date:  2019-06-21

5.  CHIP controls necroptosis through ubiquitylation- and lysosome-dependent degradation of RIPK3.

Authors:  Jinho Seo; Eun-Woo Lee; Hyerim Sung; Daehyeon Seong; Yves Dondelinger; Jihye Shin; Manhyung Jeong; Hae-Kyung Lee; Jung-Hoon Kim; Su Yeon Han; Cheolju Lee; Je Kyung Seong; Peter Vandenabeele; Jaewhan Song
Journal:  Nat Cell Biol       Date:  2016-02-22       Impact factor: 28.824

6.  MLKL Activation Triggers NLRP3-Mediated Processing and Release of IL-1β Independently of Gasdermin-D.

Authors:  Kimberley D Gutierrez; Michael A Davis; Brian P Daniels; Tayla M Olsen; Pooja Ralli-Jain; Stephen W G Tait; Michael Gale; Andrew Oberst
Journal:  J Immunol       Date:  2017-01-27       Impact factor: 5.422

7.  RIPped for neuroinflammation.

Authors:  Bart Tummers; Douglas R Green
Journal:  Cell Res       Date:  2017-05-19       Impact factor: 25.617

8.  RIPK3 Activation Leads to Cytokine Synthesis that Continues after Loss of Cell Membrane Integrity.

Authors:  Susana L Orozco; Brian P Daniels; Nader Yatim; Michelle N Messmer; Giovanni Quarato; Haiyin Chen-Harris; Sean P Cullen; Annelise G Snyder; Pooja Ralli-Jain; Sharon Frase; Stephen W G Tait; Douglas R Green; Matthew L Albert; Andrew Oberst
Journal:  Cell Rep       Date:  2019-08-27       Impact factor: 9.423

Review 9.  Programmed necrosis in the cross talk of cell death and inflammation.

Authors:  Francis Ka-Ming Chan; Nivea Farias Luz; Kenta Moriwaki
Journal:  Annu Rev Immunol       Date:  2014-12-10       Impact factor: 28.527

10.  The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.

Authors:  Silvia Alvarez-Diaz; Christopher P Dillon; Najoua Lalaoui; Maria C Tanzer; Diego A Rodriguez; Ann Lin; Marion Lebois; Razq Hakem; Emma C Josefsson; Lorraine A O'Reilly; John Silke; Warren S Alexander; Douglas R Green; Andreas Strasser
Journal:  Immunity       Date:  2016-08-11       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.